Collecting data on patients with bone metastases treated for fractures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather prospective data on the natural history of bone metastases and skeletal-related events in patients who have undergone surgical treatment for impending or pathologic fractures of long bones. It will evaluate clinical and biological factors, focusing on complication rates, functional outcomes, and survival differences based on various patient characteristics. The study will compare outcomes between those treated with intramedullary fixation and endoprosthetic reconstruction, providing insights into the effectiveness of these surgical approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with long bone metastases treated surgically with intramedullary nail or endoprosthetic reconstruction

Exclusion Criteria:

* Patients with bone metastases of the spine

Where it's running

• Istituto Ortopedico Rizzoli
  Bologna, Bologna, Italy Recruiting

Study contacts

• Principal investigator: Costantino Errani, MD — Istituto Ortopedico Rizzoli
• Study coordinator: Costantino Errani, MD
• Email: costantino.errani@ior.it
• Phone: +390516366103

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pluvicto real-world use in metastatic castration-resistant prostate cancer

  This real-world study tests how well Pluvicto works in men with metastatic castration-resistant prostate cancer in the US and Germany.

  Recruiting Novartis · East Hanover, New Jersey · NCT07697989

• Vepugratinib with enfortumab vedotin and pembrolizumab for FGFR3‑altered advanced urothelial cancer

  This trial tests whether adding vepugratinib to enfortumab vedotin and pembrolizumab helps people with advanced or metastatic urothelial (bladder) cancer who have an FGFR3 genetic change, compared with placebo.

  Recruiting at 129 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 275 other locations · NCT07218380

• Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 212 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 263 other locations · NCT07213804

• Tersolisib plus standard anti-cancer medicines for advanced HR+/HER2- breast cancer with a PIK3CA change

  This trial tests whether adding tersolisib to standard first-line anti-cancer medicines helps people with advanced hormone receptor–positive, HER2‑negative breast cancer that has a PIK3CA mutation.

  Recruiting at 179 sites Phase 3 Eli Lilly and Company · Anchorage, Alaska and 363 other locations · NCT07174336

• LY4257496 for GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer (OMNIRAY)

  This Phase 1 test tries LY4257496, with GRPR imaging using LY4257529 and sometimes standard treatments, to see if it is safe and helps people with GRPR-positive advanced breast, colorectal, prostate, or endometrial cancer.

  Recruiting at 15 sites Phase 1 Eli Lilly and Company · Duarte, California and 32 other locations · NCT07114601

• LY4175408 for selected advanced lung, endometrial, and triple‑negative breast cancers

  This trial tests an experimental drug called LY4175408 to see if it is safe and works for people with advanced or metastatic non‑small cell or small cell lung cancer, endometrial cancer, or triple‑negative breast cancer.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Stanford, California and 26 other locations · NCT07046923

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.